#United States #Menlo Park #Antheia #Biomanufacturing #Thebaine

Antheia Secures $56 Million in Series C Financing

Antheia, a pioneering manufacturer of pharmaceutical ingredients, recently announced a significant achievement in securing $56 million in Series C financing. This funding marks a strategic move to bolster its global commercialization efforts and expand its innovative biomanufacturing platform, which aims to address the persistent issue of medication shortages worldwide.

With this new capital, Antheia plans to accelerate the commercialization of its first product, thebaine—an essential compound used in various pharmaceutical applications, including the production of Narcan, a vital medication for opioid overdoses. The company has an impressive pipeline of over 70 biosynthetic pharmaceutical ingredients spanning across seven therapeutic areas, focusing specifically on essential medicines that are currently at risk of shortage.

Dr. Christina Smolke, CEO and co-founder of Antheia, expressed enthusiasm about the funding, stating, "Our industry-first biosynthetic product offerings are disrupting the market by addressing major supply chain issues and quickly cementing Antheia's position as a leading industry innovator." She emphasized the company's commitment to collaborating with investors and manufacturing partners to ensure widespread access to critical medicines through their cutting-edge biosynthesis technology.

The financing round was led by the Global Health Investment Corporation (GHIC), a U.S.-based investment firm dedicated to promoting global health and security. Other participating investors included EDBI, which is aligned with Singapore's Economic Development Board, along with significant contributions from ATHOS KG, Federov, Viking Global Investors, Sherpalo Ventures, and In-Q-Tel (IQT).

Joseph Lee, Principal at GHIC, highlighted the urgent health security challenge posed by complex global pharmaceutical supply chains and reinforced the need for innovative solutions like Antheia's biosynthesis platform. He remarked, "Antheia's platform offers a transformative solution, enabling efficient and reliable production of key starting materials and active pharmaceutical ingredients (APIs)."

Singapore has recognized its potential to lead in biotechnology innovations. Paul Ng, CEO of EDBI, stated, "As Singapore strengthens its position as Asia's biotech hub, we see significant opportunities for Antheia to expand its biomanufacturing capabilities through collaborations with the local scientific ecosystem. This partnership aims to create valuable synergies for growth across the Asian market."

The recent funding comes shortly after several notable milestones for Antheia. These milestones include the successful first commercial delivery of thebaine, solidifying Antheia's role in transforming pharmaceutical supply chains, and receiving two government project agreements aimed at domestic drug supply enhancement, cumulatively valued at $23 million. Antheia continues to emphasize its role in addressing global health challenges and modernizing pharmaceutical supply chains through biomanufacturing.

Antheia's vision is clear: to revolutionize pharmaceutical manufacturing by harnessing advanced biosynthesis and fermentation technology. By enabling the rapid production of key materials and APIs, Antheia aspires to enhance public health and improve access to essential medications worldwide. Founded in 2015, the company is poised for rapid growth as it solidifies its place as a key player in the biomanufacturing arena. For further updates on Antheia and its innovative initiatives, visit www.antheia.bio.